Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC)

Several brokerages have updated their recommendations and price targets on shares of Blueprint Medicines (NASDAQ: BPMC) in the last few weeks:

• 1/27/2025 – Blueprint Medicines had its price target raised by analysts at Piper Sandler from $109.00 to $119.00. They now have a “neutral” rating on the stock.
• 1/15/2025 – Blueprint Medicines had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
• 1/13/2025 – Blueprint Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $124.00 price target on the stock, down previously from $135.00.
• 1/13/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
• 1/2/2025 – Blueprint Medicines had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $140.00 price target on the stock.
• 12/11/2024 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/9/2024 – Blueprint Medicines had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.

Blueprint Medicines Price Performance

Shares of BPMC opened at $114.47 on Wednesday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm’s fifty day simple moving average is $96.68 and its 200-day simple moving average is $95.14. The firm has a market capitalization of $7.27 billion, a price-to-earnings ratio of -54.25 and a beta of 0.61. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the business earned ($2.20) EPS. Blueprint Medicines’s revenue for the quarter was up 126.5% compared to the same quarter last year. Equities analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares of the company’s stock, valued at $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors have recently bought and sold shares of BPMC. Wellington Management Group LLP boosted its position in Blueprint Medicines by 22.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after buying an additional 729,055 shares during the last quarter. State Street Corp raised its position in shares of Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock valued at $255,827,000 after acquiring an additional 385,818 shares in the last quarter. Geode Capital Management LLC increased its stake in Blueprint Medicines by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock valued at $136,942,000 after purchasing an additional 20,703 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Blueprint Medicines by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company’s stock valued at $55,244,000 after buying an additional 50,736 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in Blueprint Medicines by 161.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock worth $45,888,000 after acquiring an additional 306,079 shares during the period.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.